216 related articles for article (PubMed ID: 21247383)
1. Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasome system in both preclinical and clinical studies.
Kona FR; Buac D; M Burger A
Curr Cancer Drug Targets; 2011 Mar; 11(3):338-46. PubMed ID: 21247383
[TBL] [Abstract][Full Text] [Related]
2. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
Cvek B; Dvorak Z
Drug Discov Today; 2008 Aug; 13(15-16):716-22. PubMed ID: 18579431
[TBL] [Abstract][Full Text] [Related]
3. Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome.
Cvek B
Curr Cancer Drug Targets; 2011 Mar; 11(3):332-7. PubMed ID: 21247389
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitin-based anticancer therapy: carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors.
Mattern MR; Wu J; Nicholson B
Biochim Biophys Acta; 2012 Nov; 1823(11):2014-21. PubMed ID: 22610084
[TBL] [Abstract][Full Text] [Related]
5. Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents.
Ekinci E; Rohondia S; Khan R; Dou QP
Recent Pat Anticancer Drug Discov; 2019; 14(2):113-132. PubMed ID: 31084595
[TBL] [Abstract][Full Text] [Related]
6. Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activity.
Hasinoff BB; Patel D
Arch Biochem Biophys; 2017 Nov; 633():23-28. PubMed ID: 28887129
[TBL] [Abstract][Full Text] [Related]
7. [Proteasome inhibitor].
Yamamura M; Hirai T; Yamaguchi Y
Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
[TBL] [Abstract][Full Text] [Related]
8. Deubiquitinating enzymes as therapeutic targets in cancer.
Lim KH; Baek KH
Curr Pharm Des; 2013; 19(22):4039-52. PubMed ID: 23181570
[TBL] [Abstract][Full Text] [Related]
9. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
10. A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy.
Huang J; Campian JL; Gujar AD; Tran DD; Lockhart AC; DeWees TA; Tsien CI; Kim AH
J Neurooncol; 2016 Jun; 128(2):259-66. PubMed ID: 26966095
[TBL] [Abstract][Full Text] [Related]
11. New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer.
Chen D; Dou QP
Expert Opin Ther Targets; 2008 Jun; 12(6):739-48. PubMed ID: 18479220
[TBL] [Abstract][Full Text] [Related]
12. An Updated Review of Disulfiram: Molecular Targets and Strategies for Cancer Treatment.
Yang Q; Yao Y; Li K; Jiao L; Zhu J; Ni C; Li M; Dou QP; Yang H
Curr Pharm Des; 2019; 25(30):3248-3256. PubMed ID: 31419930
[TBL] [Abstract][Full Text] [Related]
13. Anticancer effects of disulfiram in T-cell malignancies through NPL4-mediated ubiquitin-proteasome pathway.
Chen C; Nie D; Huang Y; Yu X; Chen Z; Zhong M; Liu X; Wang X; Sui S; Liu Z; Tan J; Yu Z; Li Y; Zeng C
J Leukoc Biol; 2022 Oct; 112(4):919-929. PubMed ID: 35363385
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitors in cancer therapy: lessons from the first decade.
Orlowski RZ; Kuhn DJ
Clin Cancer Res; 2008 Mar; 14(6):1649-57. PubMed ID: 18347166
[TBL] [Abstract][Full Text] [Related]
15. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications.
Burger AM; Seth AK
Eur J Cancer; 2004 Oct; 40(15):2217-29. PubMed ID: 15454246
[TBL] [Abstract][Full Text] [Related]
16. The role and therapeutic implications of RING-finger E3 ubiquitin ligases in hepatocellular carcinoma.
Yin J; Zhu JM; Shen XZ
Int J Cancer; 2015 Jan; 136(2):249-57. PubMed ID: 24420637
[TBL] [Abstract][Full Text] [Related]
17. The potential of proteasome inhibitors in cancer therapy.
Sterz J; von Metzler I; Hahne JC; Lamottke B; Rademacher J; Heider U; Terpos E; Sezer O
Expert Opin Investig Drugs; 2008 Jun; 17(6):879-95. PubMed ID: 18491989
[TBL] [Abstract][Full Text] [Related]
18. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).
Kuhn DJ; Orlowski RZ; Bjorklund CC
Curr Cancer Drug Targets; 2011 Mar; 11(3):285-95. PubMed ID: 21247387
[TBL] [Abstract][Full Text] [Related]
19. Targeting ubiquitin-proteasome pathway by natural, in particular polyphenols, anticancer agents: Lessons learned from clinical trials.
Nabavi SF; Atanasov AG; Khan H; Barreca D; Trombetta D; Testai L; Sureda A; Tejada S; Vacca RA; Pittalà V; Gulei D; Berindan-Neagoe I; Shirooie S; Nabavi SM
Cancer Lett; 2018 Oct; 434():101-113. PubMed ID: 30030139
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathways: targeting proteasomal protein degradation in cancer.
Molineaux SM
Clin Cancer Res; 2012 Jan; 18(1):15-20. PubMed ID: 22019514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
